表紙
市場調査レポート

血友病Aの世界市場:2015〜2019年

Global Hemophilia A Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 341165
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
血友病Aの世界市場:2015〜2019年 Global Hemophilia A Market 2015-2019
出版日: 2015年09月30日 ページ情報: 英文 68 Pages
概要

血友病はVIIIやIXなどの凝固因子の欠乏による稀な出血性疾患です。女性よりも男性の罹患率が高く、年間40万人が罹患すると予測されています。世界の血友病A市場は2014〜2019年にかけCAGR6.25%で拡大すると予測されています。

当レポートでは、世界の血友病A市場の現況と2015〜2019年の成長見通しについて調査し、市場規模、収益動向、製品別、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 疾患概要

  • 血友病Aの理解
  • リスクファクター
  • 徴候と症状
  • 診断
  • 治療
  • 疫学

第6章 パイプラインポートフォリオ

第7章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 治療別セグメンテーション

  • 血漿由来治療
  • 組換え治療

第9章 疾患管理別セグメンテーション

  • オンデマンド治療
  • 予防法
  • 阻害剤

第10章 地域別セグメンテーション

第11章 市場促進因子

第12章 市場促進因子の影響

第13章 市場の課題

第14章 促進因子と課題の影響

第15章 市場動向

第16章 ベンダー環境

  • 競合シナリオ
  • 市場シェア分析:2014年
  • その他の注目すべきベンダー

第17章 主要ベンダー分析

  • Baxter
  • Bayer HealthCare
  • CSL Behring
  • Pfizer

第18章 付録

第19章 Technavioについて

図表

目次
Product Code: IRTNTR7382

About hemophilia A

Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.

Technavio's analysts forecast the global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.

Technavio's report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • Baxter International
  • Bayer's
  • CSL Behring
  • Novo Nordisk
  • Pfizer

Other Prominent Vendors

  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios
  • Biogen Idec
  • Catalyst Biosciences
  • Dimension Therapeutics
  • Dong-A Socio
  • Emergent BioSolutions
  • Grifols
  • Inspiration Biopharmaceuticals
  • Kedrion Biopharma
  • Octapharma
  • OPKO Health
  • rEVO Biologics
  • Sangamo BioSciences
  • Spark Therapeutics
  • UniQure

Market driver

  • Development of drugs with prolonged action
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Advances in technology
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Risk factors
  • Signs and symptoms
  • Diagnosis
  • Treatment
  • Epidemiology

PART 06: Pipeline portfolio

  • Key information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Segmentation by type of therapy

  • Plasma-derived therapies
  • Recombinant therapies

PART 09: Segmentation by disease management

  • On-demand therapy
  • Prophylaxis
  • Inhibitors

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 17: Key vendor analysis

  • Baxter
  • Bayer HealthCare
  • CSL Behring
  • Pfizer

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Number of prevalence cases of hemophilia A in five countries 2011
  • Exhibit 03: Key late-stage drugs under development for hemophilia A
  • Exhibit 04: Global hemophilia A drugs market 2014-2019 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global hemophilia A drugs market by type of therapy
  • Exhibit 07: Segmentation by type of therapy for hemophilia A
  • Exhibit 08: Global hemophilia A drugs market by disease management
  • Exhibit 09: Types of prophylaxis
  • Exhibit 10: Segmentation by disease management of hemophilia A
  • Exhibit 11: Segmentation of global hemophilia A drugs market by geography in 2014
  • Exhibit 12: Impact of drivers
  • Exhibit 13: Impact of drivers and challenges
  • Exhibit 14: Baxter: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
  • Exhibit 15: Baxter: Key takeaways
  • Exhibit 16: Novo Nordisk: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
  • Exhibit 17: Novo Nordisk: Key takeaways
  • Exhibit 18: Bayer: Global YoY growth and revenue of Kogenate FS 2012-2014 ($ millions)
  • Exhibit 19: Bayer's: Key takeaways
  • Exhibit 20: Pfizer: Global YoY growth and revenue of Xyntha/ReFactoAF 2012-2014 ($ millions)
  • Exhibit 21: Pfizer: Key takeaways
  • Exhibit 22: CSL Behring: Global YoY growth and revenue of hemophilia products 2013-2014 ($ millions)
  • Exhibit 23: CSL Behring: Key takeaways
  • Exhibit 24: CSL Behring: Product segmentation by revenue 2014
  • Exhibit 25: CSL Behring: Geographical segmentation by revenue 2014
  • Exhibit 26: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 27: Novo Nordisk: Business segmentation by revenue 2013 and 2014
  • Exhibit 28: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 29: Novo Nordisk: R&D expenditure 2014
Back to Top